– Novel Oral Plasma Kallikrein Inhibitors KV998052 and KV998054
Prevent and Reverse VEGF-Induced Retinal Edema in Mice –
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Apr. 30, 2019--
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, announced data
from a poster presentation on Monday, April 29, at the Association for
Research in Vision and Ophthalmology (ARVO) Annual Meeting 2019 in
“We are pleased to have more data confirming the ability of our oral
plasma kallikrein inhibitors to demonstrate efficacy when systemically
delivered in an animal model of retinal edema,” said Andrew Crockett,
Chief Executive Officer of KalVista. “These molecules show a dose
response and the ability to reach the back of the eye. We remain
committed to applying these learnings to bring forward in development a
potential oral treatment for diabetic macular edema.”
The poster presented data showing that two novel, orally administered
plasma kallikrein inhibitors, KV998052 and KV998054, significantly
reduce VEGF stimulated retinal edema in mice. Both compounds provided
protection of plasma kallikrein-mediated high molecular weight kininogen
Oral administration of KV998054 initiated before VEGF injection
resulted in a 59% (p=0.001) decrease in VEGF retinal thickening at 24
Oral KV998052 provided 24 hours after intravitreal injection of VEGF
accelerated resolution of edema at 72 hours by 83% (p=0.015) compared
with controls given vehicle.
Retinal segment analysis revealed that reduction in thickening by
plasma kallikrein inhibition occurred in multiple layers, including an
87% decrease in the inner nuclear layer.
Data suggest that oral administration of these plasma kallikrein
inhibitors may provide an opportunity to treat diabetic macular edema
(DME) that is caused by VEGF.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on
the discovery, development, and commercialization of small molecule
protease inhibitors for diseases with significant unmet need. The
initial focus is on inhibitors of plasma kallikrein, which is an
important component of the body’s inflammatory response and which, in
excess, can lead to increased vascular permeability, edema and
inflammation. KalVista has developed a proprietary portfolio of novel,
small molecule plasma kallikrein inhibitors initially targeting
hereditary angioedema (HAE) and diabetic macular edema (DME). The
Company has created a structurally diverse portfolio of oral plasma
kallikrein inhibitors and is advancing multiple drug candidates for HAE
as well as DME. The Company has selected KVD900 as its program to be
advanced as an on-demand therapy for HAE attacks and commenced a Phase 2
proof-of-concept study in HAE patients in late 2018. In DME, KalVista’s
most advanced program, an intravitreally administered plasma kallikrein
inhibitor known as KVD001, began a Phase 2 clinical trial in 2017 that
is anticipated to complete in the second half of 2019.
For more information, please visit www.kalvista.com.
This press release contains "forward-looking" statements within the
meaning of the safe harbor provisions of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as: "anticipate," "intend," "plan," "goal,"
"seek," "believe," "project," "estimate," "expect," "strategy,"
"future," "likely," "may," "should," "will" and similar references to
future periods. These statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially from
what we expect. Examples of forward-looking statements include, among
others, available funding, our cash runway and future clinical trial
timing and results. Further information on potential risk factors that
could affect our business and its financial results are detailed in the
annual report on Form 10-K filed on July 30, 2018 and other reports as
filed from time to time with the Securities and Exchange Commission. We
undertake no obligation to publicly update any forward-looking
statement, whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190430005273/en/
Source: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc.
Corporate Communications & Investor Relations